Affiliation:
1. Department of the Second Gynecologic Oncology, The First Affiliated Hospital of Henan Polytechnic University (The Second People’s Hospital of Jiaozuo), Jiaozuo, Henan, 454000, China
Abstract
We present a case of a 76-year-old patient with recurrent cervical cancer who underwent first-line treatment with penpulimab combined with anlotinib. The patient was diagnosed with poorly differentiated stage III C1r cervical squamous cell carcinoma and received standard cisplatin-sensitized chemoradiotherapy, subsequently achieving a good treatment effect of complete response. Recurrence occurred nearly 14 months after treatment, with multiple metastases including in the brain and lung. Oral anlotinib was less effective, but the treatment of penpulimab combined with anlotinib showed an obvious curative effect. It has been maintained for more than 17 months, and as of April 2023 the patient is still maintaining her response. Our case suggests that penpulimab combined with anlotinib has promising efficacy in the treatment of elderly patients with recurrent cervical cancer.
Funder
Henan Polytechnic University Youth Innovation exploratory Fund
Henan Province Medical Science and Technology Research Program Joint Construction Project
Subject
Oncology,Immunology,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Catequentinib/penpulimab;Reactions Weekly;2023-08-05